Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) clinical trial (NCT07058012). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of cemiplimab and the other drugs being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) clinical trial (NCT07058012). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) clinical trial (NCT07058012). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) clinical trial (NCT07058012). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests will be done to monitor my progress during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) clinical trial (NCT07058012). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or complications during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) clinical trial (NCT07058012). Contact the study team or your healthcare provider for specific answers.

What this study is about